Cardiology Research Analysis
June 2026 cardiology featured practice-ready advances alongside mechanistic diagnostics with strong translational potential. Two randomized interventions offer immediate impact: oral nicorandil reduced contrast-associated kidney injury in high-risk PCI, and the first-in-class oral inotrope AC01 showed a clean short-term safety profile in HFrEF, enabling phase-2/3 efficacy trials. Mechanistic-diagnostic work established carbon dioxide as a coordinated vasodilator and introduced NIRS-CO2 as a feas
Summary
June 2026 cardiology featured practice-ready advances alongside mechanistic diagnostics with strong translational potential. Two randomized interventions offer immediate impact: oral nicorandil reduced contrast-associated kidney injury in high-risk PCI, and the first-in-class oral inotrope AC01 showed a clean short-term safety profile in HFrEF, enabling phase-2/3 efficacy trials. Mechanistic-diagnostic work established carbon dioxide as a coordinated vasodilator and introduced NIRS-CO2 as a feasible noninvasive microvascular readout. Precision therapeutics and device strategy matured, with aficamten improving exercise physiology versus metoprolol in obstructive HCM and a sirolimus-eluting balloon strategy approaching DES outcomes at 1 year. Across the month, physiology- and imaging-led care (e.g., QFR guidance) and genetics-enabled prevention continued to refine patient selection for therapies.
Selected Articles
1. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.
In a multicenter randomized, double‑blind, placebo‑controlled phase 1b/2a trial (n=58), the oral calcium‑sensitizing ghrelin receptor agonist AC01 was safe and well tolerated over 7–28 days without tachycardia, pro‑arrhythmic signals, conduction abnormalities, or biomarker evidence of myocardial injury, supporting dose selection and progression to efficacy trials.
Impact: First randomized clinical evaluation of a safer, oral inotropic mechanism in HFrEF addresses a longstanding unmet need and de‑risks subsequent phase‑2/3 efficacy testing.
Clinical Implications: If efficacy is confirmed, AC01 could offer an outpatient inotropic option that augments contractility without the arrhythmic liabilities of traditional agents, potentially reducing hospitalizations and enabling earlier optimization of GDMT.
Key Findings
- Short‑term randomized exposure (7–28 days) showed no AC01‑related serious adverse events.
- No tachycardia, tachyarrhythmias, or ECG conduction abnormalities; no adverse hs‑troponin or NT‑proBNP signals.
- Pharmacokinetics and tolerability supported dose selection and advancement to phase‑2 efficacy testing.
2. Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI.
In a multicenter randomized trial (n=585) enrolling PCI patients with renal dysfunction, peri‑procedural oral nicorandil (5 mg TID or 10 mg TID) added to hydration reduced CA‑AKI versus hydration alone (19.8% control vs 10.9% conventional dose vs 8.7% high dose), demonstrating a dose‑response renoprotective effect.
Impact: Provides a low‑cost, scalable, and immediately implementable strategy to mitigate a common and morbid PCI complication in high‑risk patients.
Clinical Implications: Incorporate oral nicorandil (10 mg TID) into cath lab protocols for high‑risk PCI alongside hydration to lower CA‑AKI risk while longer‑term renal and clinical outcomes are evaluated.
Key Findings
- Randomized 585 patients with renal dysfunction undergoing PCI to nicorandil (5 mg or 10 mg TID) versus hydration alone.
- CA‑AKI incidence reduced from 19.8% (control) to 10.9% (5 mg TID) and 8.7% (10 mg TID).
- A clear dose‑response renoprotective effect supports favoring the higher dose regimen.
3. Carbon dioxide is a triple vasodilator.
Mechanistic experiments in mice and human vascular studies show CO2 induces vasodilation via three coordinated pathways—endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels—and introduce NIRS‑CO2 with a time‑to‑intersection (TTI) metric that correlates with PAD/CAD and captures disease‑associated microvascular delay.
Impact: Unifies CO2‑mediated vasodilatory biology and supplies a feasible noninvasive biomarker (NIRS‑CO2) with clear translational potential for bedside microvascular assessment.
Clinical Implications: NIRS‑CO2 could serve as a bedside tool to quantify integrated endothelial and myogenic microvascular function, enabling earlier diagnosis, risk stratification, and therapy monitoring; identified pathways (NO‑sGC, K+ channels, carbonic anhydrases) nominate therapeutic targets.
Key Findings
- CO2 elicits vasodilation via endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels.
- NIRS‑CO2 TTI correlates with PAD/CAD and detects delayed microvascular reactivity in disease.
- Proposes a practical, noninvasive readout that can be deployed at the bedside for vascular health monitoring.
4. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
In a phase‑3 randomized, active‑controlled trial (n=175 randomized; 165 core‑lab CPET), aficamten improved multiple exercise physiology endpoints versus metoprolol over 24 weeks, including submaximal VE/VCO2 slope, anaerobic threshold, peak workload, and VO2 recovery time, with fewer large declines in exercise capacity.
Impact: Demonstrates disease‑specific myosin inhibition yields superior physiologic gains over standard β‑blockade in obstructive HCM, foreshadowing a shift in first‑line pharmacotherapy pending long‑term outcomes.
Clinical Implications: Supports considering aficamten to improve exercise capacity in symptomatic obstructive HCM, with guideline adoption contingent on durable safety and hard clinical outcomes.
Key Findings
- Greater improvements in VE/VCO2 slope (−2.8) and anaerobic threshold (+76 mL/min) versus metoprolol.
- Higher peak workload (+8 W), faster VO2 recovery (−11 s), and more frequent large peak VO2 gains (20.5% vs 3.7%).
- Large declines in exercise capacity were less common with aficamten.
5. Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial.
In a multicenter randomized trial of 3,323 patients with de novo coronary lesions, a sirolimus‑eluting balloon (SEB) strategy with provisional stenting met prespecified noninferiority for 1‑year target vessel failure versus routine DES in ITT analysis (5.3% vs 4.4%), with ~20.7% bailout stenting and higher clinically driven revascularization; per‑protocol analysis did not confirm noninferiority.
Impact: Largest randomized evaluation of a minimal‑stent, prolonged‑release SEB strategy that could reduce permanent metal implants if long‑term outcomes remain acceptable.
Clinical Implications: Supports selective adoption of SEB with careful attention to revascularization risk and per‑protocol uncertainties while awaiting longer‑term (e.g., 5‑year) data to judge durability.
Key Findings
- ITT noninferiority for 1‑year target vessel failure: SEB 5.3% vs DES 4.4% (risk difference 0.91%).
- Bailout stenting occurred in ~20.7% of SEB cases; clinically driven TVR was higher with SEB.
- Per‑protocol analysis did not confirm noninferiority, underscoring need for longer‑term follow‑up.